Esperion Therapeutics, Inc. (ESPR)
Oxford Ledge is still expanding full research coverage of ESPR. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Esperion commercializes FDA-approved non-statin cholesterol-lowering medicines for cardiovascular disease patients globally.
SEC filings
- 8-K Entry into material agreement; Termination of material agreement; Completion of acquisition or disposition; Creation of direct financial obligation; Delisting / transfer of listing; 3.03; 5.01; Departure/election of directors or officers; Amendments to articles or bylaws; Financial statements and exhibits 2026-07-13
- 8-K Shareholder vote results 2026-07-08
- 8-K Other material event 2026-06-16
- 8-K Other material event 2026-06-09
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-01
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for ESPR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ESPR in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.